 | • レポートコード：MRC2302F0004 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、221ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートでは、2021年に2,846.90百万ドルであった世界の駆虫薬市場規模が、2022年に3,067.44百万ドルになり、2027年には4,498.60百万ドルまで、年平均7.92%で成長すると予測しています。本レポートでは、駆虫薬の世界市場について調査・分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、薬物クラス別（ベンズイミダゾール、ピペラジン）分析、投与経路別（注射可能、経口）分析、標的病原体別（十二指腸アンシロストマ、回虫、エンテロビウス バーミキュラリス、鞭毛虫）分析、用途別（動物、ヒト）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況など、以下の構成でお届けします。なお、本書には、Alkem Laboratories Limited、Amneal Pharmaceuticals Inc.、Anikem Laboratories、Arbor Pharmaceuticals Inc、AstraZeneca PLC、Boehringer Ingelheim International GmbH、Cadila Healthcare Limited、Cipla Inc.、GlaxoSmithKline PLC、Ipca Laboratories Ltd、Janssen Pharmaceuticals, Inc.、Johnson & Johnson Services, Inc.、LGM Pharma、Lupin Limited、Mankind Pharma、Merck & Co. Inc、Novartis AG、Pfizer Inc.、Sankur Pharmaceuticals Pvt. Ltd、Sanofi SA、Sun Pharmaceutical Industries Ltd、Swiss Pharma Pvt. Ltd、Virbac、Zoetis, Inc.などの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の駆虫薬市場規模：薬物クラス別 - ベンズイミダゾールの市場規模 - ピペラジンの市場規模 ・世界の駆虫薬市場規模：投与経路別 - 注射可能駆虫薬の市場規模 - 経口駆虫薬の市場規模 ・世界の駆虫薬市場規模：標的病原体別 - 十二指腸アンシロストマの市場規模 - 回虫の市場規模 - エンテロビウス バーミキュラリスの市場規模 - 鞭毛虫の市場規模 ・世界の駆虫薬市場規模：用途別 - 動物用駆虫薬の市場規模 - ヒト用駆虫薬の市場規模 ・世界の駆虫薬市場規模：地域別 - 南北アメリカの駆虫薬市場規模 アメリカの駆虫薬市場規模 カナダの駆虫薬市場規模 ブラジルの駆虫薬市場規模 ... - アジア太平洋の駆虫薬市場規模 日本の駆虫薬市場規模 中国の駆虫薬市場規模 インドの駆虫薬市場規模 韓国の駆虫薬市場規模 台湾の駆虫薬市場規模 ... - ヨーロッパ/中東/アフリカの駆虫薬市場規模 イギリスの駆虫薬市場規模 ドイツの駆虫薬市場規模 インドの駆虫薬市場規模 フランスの駆虫薬市場規模 ロシアの駆虫薬市場規模 ... - その他地域の駆虫薬市場規模 ・競争状況 ・企業情報 |
The Global Anthelmintic Drugs Market size was estimated at USD 2,846.90 million in 2021 and expected to reach USD 3,067.44 million in 2022, and is projected to grow at a CAGR 7.92% to reach USD 4,498.60 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Anthelmintic Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Drug Class, the market was studied across Benzimidazoles and Piperazine.
Based on Route of Administration, the market was studied across Injectable and Oral.
Based on Target Pathogen, the market was studied across Ancylostoma Duodenale, Ascaris Lumbricoides, Enterobius Vermicularis, and Trichuris Trichiura.
Based on Application, the market was studied across Animal and Human. The Human is further studied across Gastrointestinal Infections and Parenchymal Neurocysticercosis.
Based on Distribution Channel, the market was studied across Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Veterinary Hospitals & Clinics, and Veterinary Pharmacies.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Anthelmintic Drugs market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Anthelmintic Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Anthelmintic Drugs Market, including Alkem Laboratories Limited, Amneal Pharmaceuticals Inc., Anikem Laboratories, Arbor Pharmaceuticals Inc, AstraZeneca PLC, Boehringer Ingelheim International GmbH, Cadila Healthcare Limited, Cipla Inc., GlaxoSmithKline PLC, Ipca Laboratories Ltd, Janssen Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., LGM Pharma, Lupin Limited, Mankind Pharma, Merck & Co. Inc, Novartis AG, Pfizer Inc., Sankur Pharmaceuticals Pvt. Ltd, Sanofi SA, Sun Pharmaceutical Industries Ltd, Swiss Pharma Pvt. Ltd, Virbac, and Zoetis, Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Anthelmintic Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Anthelmintic Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Anthelmintic Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Anthelmintic Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Anthelmintic Drugs Market?
6. What is the market share of the leading vendors in the Global Anthelmintic Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Anthelmintic Drugs Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing pet adoption across the world
5.1.1.2. Increasing spending for animal healthcare and wellness
5.1.2. Restraints
5.1.2.1. Rise in drug resistance by parasitic helminths
5.1.3. Opportunities
5.1.3.1. Sponsored collaboration to fuel research activities
5.1.3.2. Increasing veterinary healthcare services centers across the world
5.1.4. Challenges
5.1.4.1. Anthelmintic resistance in sheep producing countries
5.2. Cumulative Impact of COVID-19
6. Anthelmintic Drugs Market, by Drug Class
6.1. Introduction
6.2. Benzimidazoles
6.3. Piperazine
7. Anthelmintic Drugs Market, by Route of Administration
7.1. Introduction
7.2. Injectable
7.3. Oral
8. Anthelmintic Drugs Market, by Target Pathogen
8.1. Introduction
8.2. Ancylostoma Duodenale
8.3. Ascaris Lumbricoides
8.4. Enterobius Vermicularis
8.5. Trichuris Trichiura
9. Anthelmintic Drugs Market, by Application
9.1. Introduction
9.2. Animal
9.3. Human
9.4.1. Gastrointestinal Infections
9.4.2. Parenchymal Neurocysticercosis
10. Anthelmintic Drugs Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
10.5. Veterinary Hospitals & Clinics
10.6. Veterinary Pharmacies
11. Americas Anthelmintic Drugs Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Anthelmintic Drugs Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Anthelmintic Drugs Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.1.1. Quadrants
14.1.2. Business Strategy
14.1.3. Product Satisfaction
14.2. Market Ranking Analysis, By Key Player
14.3. Market Share Analysis, By Key Player
14.4. Competitive Scenario
14.4.1. Merger & Acquisition
14.4.2. Agreement, Collaboration, & Partnership
14.4.3. New Product Launch & Enhancement
14.4.4. Investment & Funding
14.4.5. Award, Recognition, & Expansion
15. Company Usability Profiles
15.1. Alkem Laboratories Limited
15.1.1. Business Overview
15.1.2. Key Executives
15.1.3. Product & Services
15.2. Amneal Pharmaceuticals Inc.
15.2.1. Business Overview
15.2.2. Key Executives
15.2.3. Product & Services
15.3. Anikem Laboratories
15.3.1. Business Overview
15.3.2. Key Executives
15.3.3. Product & Services
15.4. Arbor Pharmaceuticals Inc
15.4.1. Business Overview
15.4.2. Key Executives
15.4.3. Product & Services
15.5. AstraZeneca PLC
15.5.1. Business Overview
15.5.2. Key Executives
15.5.3. Product & Services
15.6. Boehringer Ingelheim International GmbH
15.6.1. Business Overview
15.6.2. Key Executives
15.6.3. Product & Services
15.7. Cadila Healthcare Limited
15.7.1. Business Overview
15.7.2. Key Executives
15.7.3. Product & Services
15.8. Cipla Inc.
15.8.1. Business Overview
15.8.2. Key Executives
15.8.3. Product & Services
15.9. GlaxoSmithKline PLC
15.9.1. Business Overview
15.9.2. Key Executives
15.9.3. Product & Services
15.10. Ipca Laboratories Ltd
15.10.1. Business Overview
15.10.2. Key Executives
15.10.3. Product & Services
15.11. Janssen Pharmaceuticals, Inc.
15.11.1. Business Overview
15.11.2. Key Executives
15.11.3. Product & Services
15.12. Johnson & Johnson Services, Inc.
15.12.1. Business Overview
15.12.2. Key Executives
15.12.3. Product & Services
15.13. LGM Pharma
15.13.1. Business Overview
15.13.2. Key Executives
15.13.3. Product & Services
15.14. Lupin Limited
15.14.1. Business Overview
15.14.2. Key Executives
15.14.3. Product & Services
15.15. Mankind Pharma
15.15.1. Business Overview
15.15.2. Key Executives
15.15.3. Product & Services
15.16. Merck & Co. Inc
15.16.1. Business Overview
15.16.2. Key Executives
15.16.3. Product & Services
15.17. Novartis AG
15.17.1. Business Overview
15.17.2. Key Executives
15.17.3. Product & Services
15.18. Pfizer Inc.
15.18.1. Business Overview
15.18.2. Key Executives
15.18.3. Product & Services
15.19. Sankur Pharmaceuticals Pvt. Ltd
15.19.1. Business Overview
15.19.2. Key Executives
15.19.3. Product & Services
15.20. Sanofi SA
15.20.1. Business Overview
15.20.2. Key Executives
15.20.3. Product & Services
15.21. Sun Pharmaceutical Industries Ltd
15.21.1. Business Overview
15.21.2. Key Executives
15.21.3. Product & Services
15.22. Swiss Pharma Pvt. Ltd
15.22.1. Business Overview
15.22.2. Key Executives
15.22.3. Product & Services
15.23. Virbac
15.23.1. Business Overview
15.23.2. Key Executives
15.23.3. Product & Services
15.24. Zoetis, Inc.
15.24.1. Business Overview
15.24.2. Key Executives
15.24.3. Product & Services
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing